Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398840 · ClinicalTrials.gov registry record · Phase 1
A Study of ARQ 171 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00398840 is a Phase 1 study that was terminated before completion, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). The registered enrollment target is 14 participants.
The verdict
NCT00398840, a Phase 1 study, was terminated before completion, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.
Interventions
- DRUG ARQ 171
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)27 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398840
The ClinicalTrials.gov registry entry for NCT00398840 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ 171 is the first listed.
NCT00398840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398840 about?
NCT00398840 is a clinical study titled "A Study of ARQ 171 in Patients With Advanced Solid Tumors". This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.
What is the current status of trial NCT00398840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00398840?
The interventions under investigation include: ARQ 171 (DRUG).
Who is sponsoring clinical trial NCT00398840?
This trial is sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.